Efficacy of Acupuncture on Chemotherapy-Induced Peripheral Neuropathy (CIPN)-TMANH

This three-armed, multicenter, randomized, parallel, sham-controlled clinical trial will conduct in three centers in Taiwan. The investigators will randomly assign 234 eligible patients into three groups, an acupuncture group (n=90), a sham-controlled group (n=90), and a waitlist-controlled group (n=54). 46 cases are expected to be received at Tainan Municipal Annan Hospital. Each subject maintain the regular treatments of cancer except the chemotherapeutic agents designed in our design. The acupuncture group and the sham-controlled group will receive three therapeutic sessions each week for four weeks, and another two sessions each week for four weeks (a total of 20 sessions at eight weeks). Each group will be followed-up for four weeks, to evaluate the persistent efficacy of acupuncture. The sham-controlled group will be performed with minimal acupuncture (superficial needling) at non-acupoints. The primary outcome measurement will be the changes in the FACT-Ntx subscale from baseline to 20th acupuncture sessions. The secondary outcome will be the changes in BPI-SF average pain score from baseline to 20th acupuncture sessions. The third outcome will be the changes of target forces by von-Frey filament test at each point in hands and feet from baseline to 20th acupuncture treatments. from baseline to 20th sessions. FACT-Ntx scale and BPI-SF average pain score will be measured at four time-points, including baseline, the end of the 12th treatments, the end of the 20th treatments, and the end of the study at the 12th week. The von-Frey filament test will be measured at three-time points, including baseline, the end of the 20th treatments, and the end of the study at the 12th week.

NCT Number	NCT07693335
Lead Sponsor	Taiwan Municipal An-Nan Hospital-China Medical University Collaborators: Taipei Veterans General Hospital, Taiwan, China Medical University Hospital
Conditions	Chemotherapy-induced Peripheral Neuropathy (CIPN), Acupuncture
Enrollment	28 participants
Start Date	2021-03-01
Primary Completion	2025-02-10 (estimated)
Study Completion	2025-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-13